NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength (Descending) | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
67457-0769-02 | 67457-0769 | ONDANSETRON HYDROCHLORIDE | ONDANSETRON HYDROCHLORIDE | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | Dec. 31, 2017 | In Use | |
00069-3033-20 | 00069-3033 | Doxorubicin Hydrochloride | Doxorubicin Hydrochloride | 2.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | Dec. 23, 1987 | July 31, 2024 | In Use |
63629-9530-01 | 63629-9530 | Doxorubicin hydrochloride | Doxorubicin hydrochloride | 2.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | Dec. 12, 2022 | April 30, 2024 | In Use |
63629-9531-01 | 63629-9531 | Doxorubicin hydrochloride | Doxorubicin hydrochloride | 2.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | Dec. 22, 2022 | April 30, 2024 | In Use |
70860-0776-02 | 70860-0776 | Ondansetron hydrochloride | Ondansetron | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | June 30, 2018 | Oct. 31, 2025 | In Use |
70860-0777-20 | 70860-0777 | Ondansetron hydrochloride | Ondansetron | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | March 1, 2018 | Feb. 28, 2023 | In Use |
70860-0777-21 | 70860-0777 | Ondansetron hydrochloride | Ondansetron | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | Feb. 15, 2021 | Nov. 30, 2025 | In Use |
00338-9581-02 | 00338-9581 | Doxorubicin hydrochloride | Doxorubicin hydrochloride, Liposomal | 2.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | Dec. 19, 2023 | In Use | |
81607-0006-07 | 81607-0006 | Arsenic trioxide | ARSENIC TRIOXIDE | 2.0 mg/mL | Chemotherapy | Miscellaneous Agent | PML/RARa | Intravenous | May 31, 2023 | In Use | |
82449-0200-03 | 82449-0200 | Ondansetron hydrochloride | Ondansetron hydrochloride | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | Sept. 30, 2023 | In Use |
Found 10,000 results in 13 milliseconds — Export these results